Current 5-MeO-DMT Clinical Trials
MEO101
Usona has completed all dosing sessions for participants in our phase 1, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), administered by intramuscular injection in healthy volunteers.
Clinical conduct of MEO101 is complete, and the study is closed to enrollment. We are currently analyzing the data from this study.
To learn more about the study please visit www.clinicaltrials.gov.
5-MeO-DMT Overview
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive indolealkylamine that is produced by a number of plants and animal, but is best known to be present, along with its active, O-demethylated metabolite bufotenine, in the skin glands of a certain toxic desert toad (Incilius alvarius, formerly Bufo alvarius).
5-MeO-DMT, first synthesized in 1936 (Hoshino 1936), is closely related in structure to serotonin (5-hydroxytryptamine [5-HT]), and therefore has a similar molecular structure to the classic psychedelics DMT (N,N-dimethyltryptamine) and psilocybin. However, its pharmacological activity may be distinct; 5-MeO-DMT works mainly as a selective serotonin receptor agonist at both 5-HT1A and 5-HT2A receptors, with functional dominance of the 5 HT1A subtype being suggested by numerous researchers (Spencer 1987, Winter 2000, Krebs-Thomson 2006, Shen 2010a).
Extensive reports of 5-MeO-DMT use in epidemiological studies and surveys of recreational/spiritual/medicinal uses (Weil 1994, Shulgin 1997, Barsuglia 2018, Davis 2018, Cox 2018a, Cox 2018b, Davis 2019, Uthaug 2019). Evidence from these studies suggest that 5-MeO-DMT use may be related to self-reported improvement of a variety of mental health symptoms including anxiety, depression, substance use problems, and PTSD (Davis 2018, Cox 2018a, Cox 2018b, Davis 2019, Uthaug 2019).
As a potentially potent, fast-acting agent with short duration of psychedelic effect in humans, 5-MeO-DMT may have significant health care implications due to cost-savings and increased patient accessibility.
Psilocybin
Learn about our work with psilocybin, another promising psychedelic compound.
